Key result
ACEI/ARB exposure shows no association with increased in-hospital mortality in COVID-19 patients.
Why the study?
Conflicting findings have raised concerns regarding the association of ACEI and ARB use with likelihood or severity of Covid-19 infection.
Meta-Analysis (n=23,822)
Yes
Odds Ratio: 1.03 (95% CI 0.69–1.55)
p-value: p=0.87
No takes yet. Share an insight, caveat, or question.
Supports continuing ACEI/ARB in COVID-19 without discontinuation; confirms safety and bolsters guideline-endorsed practice.
Garg et al. (2020) conducted a meta-analysis in Covid-19 (n=23,822). ACEI/ARB vs. Non-users of ACEI/ARB was evaluated on In-hospital mortality (OR 1.03, 95% CI 0.69-1.55, p=0.87). ACEI/ARB exposure was not associated with increased odds of in-hospital mortality (OR 1.03) compared to non-users among patients with confirmed Covid-19.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: